Median number and percentage of weeks with clinically relevant platelet counts with rilzabrutinib monotherapy or plus concomitant ITP medication in the LTE
| Median weeks with platelet counts, n (%) . | Rilzabrutinib monotherapy (n = 5) . | Rilzabrutinib + concomitant ITP medication (n = 11) . | ||
|---|---|---|---|---|
| Time in LTE | 3 mo | 6 mo | 3 mo | 6 mo |
| Platelet counts increased ≥20 × 109/L above baseline | 11 (100) | 21 (100) | 13 (100) | 21 (96) |
| Platelet counts ≥30 × 109/L | 12 (100) | 21 (99) | 13 (100) | 21 (94) |
| Platelet counts ≥50 × 109/L | 11 (100) | 20 (95) | 13 (100) | 19 (85) |
| Median weeks with platelet counts, n (%) . | Rilzabrutinib monotherapy (n = 5) . | Rilzabrutinib + concomitant ITP medication (n = 11) . | ||
|---|---|---|---|---|
| Time in LTE | 3 mo | 6 mo | 3 mo | 6 mo |
| Platelet counts increased ≥20 × 109/L above baseline | 11 (100) | 21 (100) | 13 (100) | 21 (96) |
| Platelet counts ≥30 × 109/L | 12 (100) | 21 (99) | 13 (100) | 21 (94) |
| Platelet counts ≥50 × 109/L | 11 (100) | 20 (95) | 13 (100) | 19 (85) |